Understand the source comparison
Peptides for IBS: Comparison Table
KPV (lysine-proline-valine) Inhibits NF-κB inflammatory signaling; melanocortin receptor agonist Oral (enteric-coated) or subcutaneous 500 mcg 3x daily (oral); 200–300 mcg daily (subQ) Pilot human trial in IBD; animal models in colitis Strongest evidence for m
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (lysine-proline-valine)
- Inhibits NF-κB inflammatory signaling; melanocortin receptor agonist
- Oral (enteric-coated) or subcutaneous
- 500 mcg 3x daily (oral); 200–300 mcg daily (subQ)
- Pilot human trial in IBD; animal models in colitis
- Strongest evidence for mucosal inflammation; limited IBS-specific data
- BPC-157
- Promotes angiogenesis and epithelial repair via VEGF and FAK pathways
- Subcutaneous injection
- 250–500 mcg daily
- Animal models only; no human IBS trials
- Promising for barrier restoration; entirely preclinical for IBS
- LL-37 (cathelicidin)
- Antimicrobial and immune modulation; alters microbiota composition
- 50–200 mcg daily (estimated from animal models)
- In vitro and animal studies; no human IBS data
- Addresses dysbiosis component; availability limited
- Thymosin Beta-4
- Tissue repair and anti-inflammatory; promotes actin polymerization
- 2–5 mg twice weekly
- Animal wound healing studies; no IBS-specific research
- Theoretical benefit for mucosal healing; no direct IBS evidence